drugset / Trial / NCT03497897

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897

Phase 2 Completed 66 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.

Timeline

Start
2018-09-10
Primary completion
2022-02-24
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LYS006 Unknown 2 mg Oral
Subject LYS006 Unknown 20 mg Oral

Indications